Life Molecular Imaging has signed a licensing deal with Biokosmos that gives the company rights to make and distribute the radiopharmaceutical Neuraceq (F-18 florbetaben) in the Balkans.
Biokosmos will start manufacturing Neuraceq, an agent approved for use in PET imaging to detect beta-amyloid plaques in the brain, at its sites in Athens and Thessaloniki, Greece, as soon as the necessary authorizations from authorities have been obtained. Biokosmos will distribute the imaging agent in Greece, Bulgaria, North Macedonia, and Albania.
Neuraceq is an approved imaging agent for the detection of beta-amyloid plaques in the brain that is used in clinical routine and is also an imaging biomarker for the appropriate characterization of subjects enrolled in clinical trials to support drug development in neurodegenerative diseases, noted Life Molecular Imaging.
